Mark Bagnall
Fondateur chez Naia Rare Diseases LLC
Postes actifs de Mark Bagnall
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Ativa Medical Corp.
 Ativa Medical Corp. Medical SpecialtiesHealth Technology Ativa Medical Corp. provides medical diagnostic solutions. It offers analyzers that perform critical hematology and clinical chemistry tests; and disposable test cards for trauma, pediatric, oncology and geriatric patients. The company was founded by David W. Deetz in 2008 and is headquartered in St. Paul, MN. | Directeur/Membre du Conseil | 19/11/2014 | - |
Naia Rare Diseases LLC
 Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Directeur des opérations | 01/01/2014 | - |
| Fondateur | 01/01/2014 | - | |
| Directeur Financier/CFO | 01/01/2014 | - | |
XCR Diagnostics, Inc.
 XCR Diagnostics, Inc. Medical SpecialtiesHealth Technology XCR Diagnostics, Inc. develops and delivers molecular diagnostic systems. The firm offers assays in development, portable nucleic acid testing, and sample delivery system services. The company was founded in April 2015 and is headquartered in Salt Lake City, UT. | Président | - | - |
Phenomix Sciences LLC
 Phenomix Sciences LLC Medical/Nursing ServicesHealth Services Phenomix Sciences LLC engages in the provision of healthcare solutions to enable personalized management of chronic diseases. The company was founded by Andres Acosta and Michael Camilleri in 2017 and is headquartered in St. Paul, MN. | Directeur Général | 01/02/2021 | - |
Phenomix Sciences, Inc.
 Phenomix Sciences, Inc. BiotechnologyHealth Technology Phenomix Sciences, Inc. develops data-driven precision medicine that individualizes obesity treatment. The company is based in Menlo Park, CA. The company was founded by Andres Acosta and Michael Camilleri. The CEO is Mark N. K. Bagnall. | Directeur Général | - | - |
Historique de carrière de Mark Bagnall
Anciens postes connus de Mark Bagnall
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| THERMOGENESIS HOLDINGS, INC. | Directeur/Membre du Conseil | 01/07/2016 | 03/11/2016 |
| VIA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 05/06/2007 | 01/01/2011 |
| Independent Dir/Board Member | - | 01/01/2011 | |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Directeur Financier/CFO | 24/08/2009 | 24/08/2009 |
Forticell Bioscience, Inc.
 Forticell Bioscience, Inc. BiotechnologyHealth Technology Forticell Bioscience, Inc. focuses on advanced regenerative medicine and stem cell therapy. The company was founded in 1991 and is headquartered in Englewood Cliffs, NJ. | Directeur/Membre du Conseil | 01/07/2007 | 19/11/2008 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░ ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░░░ | ░░░░░░░░░░ | - |
Formation de Mark Bagnall
| University of California, Berkeley | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 16 |
Opérationnelle
| Director/Board Member | 5 |
| Director of Finance/CFO | 3 |
| Chief Executive Officer | 3 |
Sectorielle
| Health Technology | 13 |
| Health Services | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VIA PHARMACEUTICALS, INC. | Health Technology |
| THERMOGENESIS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Forticell Bioscience, Inc.
Forticell Bioscience, Inc. BiotechnologyHealth Technology Forticell Bioscience, Inc. focuses on advanced regenerative medicine and stem cell therapy. The company was founded in 1991 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
GENTURAdx USA, Inc.
 GENTURAdx USA, Inc. Medical SpecialtiesHealth Technology GENTURAdx USA, Inc. manufactured biotechnology instruments. The firm provided tools necessary for detection and treatment of diseases and drug discoveries. It had offices in the Silicon Valley, Hong Kong, Shanghai and Suzhou. The company was founded by Steve Yu and Jesus Ching in June 2005 and was headquartered in Hayward, CA. | Health Technology |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Metrika, Inc.
 Metrika, Inc. BiotechnologyHealth Technology Metrika Inc. manufactures and markets disease-monitoring products. It also manufactures other chronic condition products. The company was founded in 1994 by Michael P. Allen and is headquartered in Sunnyvale, CA. | Health Technology |
Progenitor, Inc.
 Progenitor, Inc. BiotechnologyHealth Technology Progenitor, Inc. is an American private company. The firm develops pharmaceutical compounds for nervous system. The company is headquartered in Columbus, OH. | Health Technology |
Somatix Therapy Corp.
 Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Health Technology |
Ativa Medical Corp.
Ativa Medical Corp. Medical SpecialtiesHealth Technology Ativa Medical Corp. provides medical diagnostic solutions. It offers analyzers that perform critical hematology and clinical chemistry tests; and disposable test cards for trauma, pediatric, oncology and geriatric patients. The company was founded by David W. Deetz in 2008 and is headquartered in St. Paul, MN. | Health Technology |
Naia Rare Diseases LLC
Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Health Services |
XCR Diagnostics, Inc.
XCR Diagnostics, Inc. Medical SpecialtiesHealth Technology XCR Diagnostics, Inc. develops and delivers molecular diagnostic systems. The firm offers assays in development, portable nucleic acid testing, and sample delivery system services. The company was founded in April 2015 and is headquartered in Salt Lake City, UT. | Health Technology |
Phenomix Sciences LLC
Phenomix Sciences LLC Medical/Nursing ServicesHealth Services Phenomix Sciences LLC engages in the provision of healthcare solutions to enable personalized management of chronic diseases. The company was founded by Andres Acosta and Michael Camilleri in 2017 and is headquartered in St. Paul, MN. | Health Services |
Phenomix Sciences, Inc.
Phenomix Sciences, Inc. BiotechnologyHealth Technology Phenomix Sciences, Inc. develops data-driven precision medicine that individualizes obesity treatment. The company is based in Menlo Park, CA. The company was founded by Andres Acosta and Michael Camilleri. The CEO is Mark N. K. Bagnall. | Health Technology |
- Bourse
- Insiders
- Mark Bagnall
- Expérience
